|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0017278,
umls-concept:C0019704,
umls-concept:C0020971,
umls-concept:C0021027,
umls-concept:C0030362,
umls-concept:C0205263,
umls-concept:C0206243,
umls-concept:C0401925,
umls-concept:C0567416,
umls-concept:C1422036,
umls-concept:C1521761
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1995-2-22
|
|
pubmed:abstractText |
The hypervariable region 3 (V3) within the disulfide-bridged loop of the envelope protein of the human immunodeficiency virus type 1 (HIV-1) contains an amino acid sequence that was defined as a principal neutralizing determinant (PND). A 19-amino acid residue consensus sequence (designated V3C) predicted from the PND sequences of 245 isolates as well as a sequence from the PND of the WMJ2 HIV-1 isolate (designated V3M) were expressed on the variable region of murine-human immunoglobulin (Ig) chimeras that were designated Ig-V3C and Ig-V3M, respectively. The HIV-1 sequences on the Ig chimeras preserved their antigenicity and interacted with antibodies specific for peptides encompassing the V3C and V3M sequences. In baboons, Ig-V3C and Ig-V3M induced antibodies that bound V3C and V3M peptides as well as the glycoprotein gp120 envelope protein of HIV-1 MN isolate. In addition, the baboons' antisera were able to prevent infection of CD4 SupT1 susceptible T cells by HIV-1 MN. Finally, Ig-V3M chimeras were able to stimulate in vitro production of antibodies specific for the HIV-1 envelope-derived peptides by lymphocytes from HIV-1-infected human subjects.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1370844,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1375250,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1380094,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1563093,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1722497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-1722499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2046750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2062842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2190315,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2392685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2452447,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2455898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2460859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2464961,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-2542797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3008001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3008002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3018753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3103124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3138110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-3139886,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-6189183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-7678469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-8160009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-8216851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-8228825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831341-8265609
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
631-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7831341-AIDS Vaccines,
pubmed-meshheading:7831341-Amino Acid Sequence,
pubmed-meshheading:7831341-Animals,
pubmed-meshheading:7831341-HIV Antibodies,
pubmed-meshheading:7831341-HIV Envelope Protein gp120,
pubmed-meshheading:7831341-HIV Infections,
pubmed-meshheading:7831341-HIV-1,
pubmed-meshheading:7831341-Humans,
pubmed-meshheading:7831341-Immunization,
pubmed-meshheading:7831341-Immunodominant Epitopes,
pubmed-meshheading:7831341-Immunoglobulins,
pubmed-meshheading:7831341-Male,
pubmed-meshheading:7831341-Mice,
pubmed-meshheading:7831341-Molecular Sequence Data,
pubmed-meshheading:7831341-Papio,
pubmed-meshheading:7831341-Peptide Fragments,
pubmed-meshheading:7831341-Protein Engineering,
pubmed-meshheading:7831341-Recombinant Fusion Proteins,
pubmed-meshheading:7831341-Vaccines, Synthetic
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
|
|
pubmed:affiliation |
Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
